CoChat

Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer

Cristóbal, Ion, Rincón, Raúl, Manso, Rebeca, Caramés, Cristina, Zazo, Sandra, Madoz-Gúrpide, Juan, Rojo, Federico, García-Foncillas, Jesús · 2015 · Clinical Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Abstract

Purpose: SET is an endogenous PP2A inhibitor that might represent a novel molecular target for antitumor therapy. The aim of this study was to evaluate the molecular effects of SET deregulation and its potential clinical significance in metastatic colorectal cancer (mCRC). Experimental Design: We studied the biologic effects of SET on cell growth, colonosphere formation, caspase activity, PP2A activation status, and sensitivity to oxaliplatin and FTY720 treatments. Moreover, we analyzed SET expression by immunostaining in 242 patients with mCRC. Results: SET deregulation promotes cell growth and colonosphere formation and inhibits PP2A, thereby impairing its antitumor effects. Moreover, SET reduces sensitivity to oxaliplatin in colorectal cancer cell lines, which is restored after FTY720 treatment. SET overexpression was detected in 24.8% (60 of 242) of patients with mCRC and determined significantly shorter overall (8.6 vs. 27 months; P < 0.001) and progression-free survival (7.1 vs. 13.7 months; P < 0.001), and poor response to oxaliplatin-based chemotherapy (P = 0.004). Interestingly, its prognostic value was particularly evident in patients younger than 70 years and in those harboring KRAS mutations. Conclusions: SET overexpression is a frequent event in mCRC that plays a potential oncogenic role associated with worse outcome and resistance to oxaliplatin. Moreover, this alteration defines a subgroup of patients who could benefit from therapies containing PP2A activators such as FTY720. Clin Cancer Res; 21(2); 347–56. ©2014 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0724

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Cited by

See all 78

Metadata

Authors
Cristóbal, I., Rincón, R., Manso, R., Caramés, C., Zazo, S., Madoz-Gúrpide, J., Rojo, F., & García-Foncillas, J.
Affiliations
  • Hospital Universitario Fundación Jiménez Díaz (ES)
  • 2Pathology Department, IIS “Fundación Jiménez Diaz,” UAM, Madrid, Spain.
  • 1Translational Oncology Division, Oncohealth institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital “Fundacion Jimenez Diaz,” Madrid, Spain.
Venue
Clinical Cancer Research
Published
2015-01-14
Volume
21
Issue
2
Pages
347-356
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2083832170
Cited by
78
References
41
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 11 · 2020: 4 · 2019: 11 · 2018: 10 · 2017: 5 · 2016: 8 · 2015: 5
FWCI
2.90
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Instituto de Salud Carlos III
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
sets, PP2A inhibitors, metastatic colorectal cancer, oxaliplatin resistance, fingolimod, PP2A activation, prognostic factors, KRAS mutation, caspase activity, cell growth, chemotherapy response
MeSH terms
Oxaliplatin, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, DNA-Binding Proteins, Female, Humans, Liver Neoplasms, Male, Middle Aged, Organoplatinum Compounds, Retrospective Studies, Transcription Factors, Colorectal Neoplasms, Gene Expression, Proportional Hazards Models, Treatment Outcome, Disease-Free Survival, Drug Resistance, Neoplasm, Inhibitory Concentration 50, Cell Line, Tumor, Kaplan-Meier Estimate, Protein Phosphatase 2, Histone Chaperones, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0724
The paper
Cristóbal, I., Rincón, R., Manso, R., Caramés, C., Zazo, S., Madoz-Gúrpide, J., Rojo, F., & García-Foncillas, J. (2015). Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0724

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.